 FLORHAM PARK, N.J., June 03, 2021 GLOBE NEWSWIRE -- PDS Biotechnology Corporation Nasdaq: PDSB, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced the protocol amendment to expand its Phase 2 VERSATILE-002 study to include patients, in an additional arm, who have failed prior checkpoint inhibitor CPI therapy CPI refractory patients. The VERSATILE-002 study is designed to evaluate PDS0101 in combination with KEYTRUDA pembrolizumab in the treatment of advanced human papillomavirus HPV-associated head and neck cancer and is currently being run at approximately 20 clinical sites in the US. 